Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Cella Therapeutics
United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Cella Therapeutics is an early-stage/Pre-clinical biotech developing ophthalmic and other therapies based on small molecules and a novel AAV gene therapy platform; its preclinical asset VT-501 targets FasL and TNF-α for macular dystrophy/AMD, and it has out-licensed multiple investigational ophthalmic assets to Visus Therapeutics for glaucoma and AMD.
- Therapeutic areas
- Ophthalmology
- Modalities
- Small moleculeGene therapy
- Industry
- Biotech
02
Partnerships
Visus Therapeutics (worldwide exclusive license for an array of investigational ophthalmic therapies for glaucoma and AMD)
Beyond the preview
Go deeper on Cella Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cella Therapeutics.